of the demonetisation and currency shortfall affecting retail trade off takes. My guess overall - Q3 shud be similar to Q2 or slightly better in overall earnings. Q4 shud be a blockbuster. Let`s see how it unfolds For the upcoming week - all eyes and ears will be on the Kothur FDA outcome and TAD update on Mylan`s g
12.13 PM Jan 21st
My understanding is that all the generic challengers for the 40 mg are basing an argument that the 40 mg just an increased strength and not a different formulation per se than the 20 mg (what Teva is claiming). That said Mylan needs to get an approval for the 20 mg which has taken a very long time
12.45 PM Jan 19th
Teva has sued Mylan for alleged patent infringement over Copaxone (glatiramer acetate injection), a treatment for patients with relapsing-remitting forms of multiple sclerosis.The case, which was filed yesterday, January 17, at the US District Court for the Northern District of West Virginia
11.08 AM Jan 19th
Copyright © e-Eighteen.com Ltd. All rights reserved. Reproduction of news articles, photos, videos or any other content in whole or in part in any form or medium without express written permission of moneycontrol.com is prohibited.